TITLE

HEMONC TODAY's blogger talks about early stop to ESCAPE trial

AUTHOR(S)
Campbell, Toby
PUB. DATE
March 2008
SOURCE
Hem/Onc Today;3/10/2008, Vol. 9 Issue 4, p4
SOURCE TYPE
Newspaper
DOC. TYPE
Editorial
ABSTRACT
The author discusses the early closing of Bayer's phase-3 ESCAPE (Evaluation of Sorafenib, Carboplatin, And Paclitaxel Efficacy) trial evaluating the role of sorafenib in combination with chemotherapy in metastatic non-small cell lung cancer (NSCLC). He reveals the reason for the closing. The author is positive that many future studies will plan for stratification for histology in an attempt to continue to refine the treatment for NSCLC.
ACCESSION #
31672179

 

Related Articles

  • Drug Discovery. Nutan Prakash; Patel Devangi // Journal of Antivirals & Antiretrovirals;2010, Vol. 2 Issue 4, p63 

    The drug industry is one of the major players guiding the development of the medicines, biotechnology & pharmacology field. Drug discovery is the process by which drugs are discovered and designed. It is a process which aims at identifying a compound therapeutically useful in curing & treating...

  • Systems biology and combination therapy in the quest for clinical efficacy. Fitzgerald, Jonathan B.; Schoeberl, Birgit; Nielsen, Ulrik B.; Sorger, Peter K. // Nature Chemical Biology;Sep2006, Vol. 2 Issue 9, p458 

    Combinatorial control of biological processes, in which redundancy and multifunctionality are the norm, fundamentally limits the therapeutic index that can be achieved by even the most potent and highly selective drugs. Thus, it will almost certainly be necessary to use new 'targeted'...

  • Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan? Maeda, Hideki; Kurokawa, Tatsuo // International Journal of Clinical Oncology;Dec2015, Vol. 20 Issue 6, p1072 

    Background: This study exhaustively and historically investigated the status of drug lag for oncology drugs approved in Japan. Methods: We comprehensively investigated oncology drugs approved in Japan between April 2001 and July 2014, using publicly available information. We also examined...

  • Colocalized Delivery of Rapamycin and Paclitaxel to Tumors Enhances Synergistic Targeting of the PI3K/Akt/mTOR Pathway. Blanco, Elvin; Sangai, Takafumi; Wu, Suhong; Hsiao, Angela; Ruiz-Esparza, Guillermo U; Gonzalez-Delgado, Carlos A; Cara, Francisca E; Granados-Principal, Sergio; Evans, Kurt W; Akcakanat, Argun; Wang, Ying; Do, Kim-Anh; Meric-Bernstam, Funda; Ferrari, Mauro // Molecular Therapy;Jul2014, Vol. 22 Issue 7, p1310 

    Ongoing clinical trials target the aberrant PI3K/Akt/mammalian target of rapamycin (mTOR) pathway in breast cancer through administration of rapamycin, an allosteric mTOR inhibitor, in combination with paclitaxel. However, synergy may not be fully exploited clinically because of distinct...

  • Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO. Sehouli, Jalid; Stengel, Dirk; Mustea, Alexander; Camara, Oumar; Keil, Elke; Elling, Dirk; Ledwon, Peter; Christiansen, Bernd; Klare, Peter; Gebauer, Gerhard; Schwarz, Marina; Lichtenegger, Werner // Cancer Chemotherapy & Pharmacology;Feb2008, Vol. 61 Issue 2, p243 

    To study the toxicity and efficacy of weekly paclitaxel and carboplatin (PC-W) in women with primary ovarian cancer This investigation extended a phase-I dose finding study and was approved by the institutional review boards of all participating institutions. Between 1999 and 2003, women with...

  • Paclitaxel chemotherapy for the treatment of gastric cancer. Sakamoto, Junichi; Matsui, Takanori; Kodera, Yasuhiro // Gastric Cancer;Jun2009, Vol. 12 Issue 2, p69 

    A comprehensive review of phase I and phase II clinical trials of paclitaxel and paclitaxel-containing chemotherapy regimens for advanced gastric cancer was performed. Response rates, median progression-free survivals, and median overall survivals were examined, together with the treatment...

  • Biothera Phase II Lung Cancer Trial Fully Enrolled.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p351 

    The article reports on the enrollment of Biothera's Phase II nonsmall cell lung cancer (NSCLC) clinical trial evaluating Imprime PGG administered in combination with cetuximab (Erbitux), carboplatin and paclitaxel in Eagan, Minnesota. It states that the trial evealuates the safety and efficacy...

  • Proximagen Stands to Get $232M in Deal for Parkinson's Drug. Moran, Nuala // BioWorld Today;7/15/2008, Vol. 19 Issue 136, p1 

    The article reports on the development deal reached by Proximagen Neuroscience plc with Upsher-Smith Laboratories Inc. in July 2008. The deal is geared toward the development of PRX1, which is a preclinical-stage compound for the symptomatic treatment of Parkinson's disease. The benefits of the...

  • Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer. Pisano, Carmela; Cecere, Sabrina Chiara; Di Napoli, Marilena; Cavaliere, Carla; Tambaro, Rosa; Facchini, Gaetano; Scaffa, Cono; Losito, Simona; Pizzolorusso, Antonio; Pignata, Sandro // Journal of Drug Delivery;2013, p1 

    Among the pharmaceutical options available for treatment of ovarian cancer, increasing attention has been progressively focused on pegylated liposomal doxorubicin (PLD), whose unique formulation prolongs the persistence of the drug in the circulation and potentiates intratumor accumulation....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics